{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T20:26:13Z","timestamp":1782764773496,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.dld.2016.06.018","type":"journal-article","created":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T21:48:47Z","timestamp":1466718527000},"page":"1078-1081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Predictive factors of poor response to therapy in Autoimmune Hepatitis"],"prefix":"10.1016","volume":"48","author":[{"given":"Paolo","family":"Muratori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudine","family":"Lalanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Muratori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2016.06.018_bib0135","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12470","article-title":"Review article: autoimmune hepatitis \u2013 current management and challenges","volume":"38","author":"Zachou","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.06.018_bib0140","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2016.06.018_bib0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","article-title":"Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis","volume":"21","author":"Kirk","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.dld.2016.06.018_bib0150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Quarterly Journal of Medicine"},{"key":"10.1016\/j.dld.2016.06.018_bib0155","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2016.06.018_bib0160","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0165","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","article-title":"Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs","volume":"36","author":"Selvarajah","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.06.018_bib0170","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0175","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3109\/00365521.2014.998271","article-title":"Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use","volume":"50","author":"Ytting","year":"2015","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.06.018_bib0180","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-015-4022-0","article-title":"Refractory autoimmune hepatitis: beyond standard therapy","author":"Rubin","year":"2016","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.dld.2016.06.018_bib0185","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0190","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","article-title":"Autoimmune hepatitis in Italy: the Bologna experience","volume":"50","author":"Muratori","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0195","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2036.2005.02488.x","article-title":"Clinical features of type 1 autoimmune hepatitis in elderly Italian patients","volume":"21","author":"Granito","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.06.018_bib0200","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2006.03104.x","article-title":"Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study","volume":"24","author":"Floreani","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2016.06.018_bib0205","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/0891693021000054066","article-title":"Smooth muscle antibodies and type 1 autoimmune hepatitis","volume":"35","author":"Muratori","year":"2002","journal-title":"Autoimmunity"},{"key":"10.1016\/j.dld.2016.06.018_bib0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","article-title":"Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome","volume":"42","author":"Feld","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0215","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/hep.27983","article-title":"Prediction of short- and long-term outcome in patients with autoimmune hepatitis","volume":"62","author":"Kirstein","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0220","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.25658","article-title":"Long-term outcome of Japanese patients with type 1 autoimmune hepatitis","volume":"56","author":"Yoshizawa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0225","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/hep.26290","article-title":"Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study","volume":"57","author":"Ngu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0230","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/ard.2006.056937","article-title":"Sex: a major predictor of remission in early rheumatoid arthritis?","volume":"66","author":"Forslind","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2016.06.018_bib0235","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","article-title":"Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission, and plasma cell activity in the liver biopsy","volume":"99","author":"Verma","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2016.06.018_bib0240","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/jhep.2002.32092","article-title":"Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease","volume":"35","author":"Ma","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0896-8411(03)00084-2","article-title":"Low frequency of anti-SLA\/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay","volume":"21","author":"Miyakawa","year":"2003","journal-title":"Journal of Autoimmunity"},{"key":"10.1016\/j.dld.2016.06.018_bib0250","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/liv.12658","article-title":"Anti-SLA\/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis","volume":"35","author":"Zachou","year":"2015","journal-title":"Liver International"},{"key":"10.1016\/j.dld.2016.06.018_bib0255","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.26666","article-title":"Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis","volume":"59","author":"Couto","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2016.06.018_bib0260","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/liv.12022","article-title":"Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study","volume":"33","author":"Efe","year":"2013","journal-title":"Liver International"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816304777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865816304777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T03:45:43Z","timestamp":1568087143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865816304777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1590865816304777"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2016.06.018","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive factors of poor response to therapy in Autoimmune Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2016.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}